Drug developer Aastrom (ASTM +5.2%) is trading higher after saying the 12-month follow-up data...
Drug developer Aastrom (ASTM +5.2%) is trading higher after saying the 12-month follow-up data from clinical trials for its drug ixmyelocel-T showed that treatment was well-tolerated, and efficacy observations were consistent with improved heart function.
From other sites
at MarketWatch.com (Jan 2, 2013)
at MarketWatch.com (Sep 6, 2012)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs